Suchergebnisse - "Roeker, Lindsey E"

PubPharm (6)

1

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

enthalten in: Science (New York, N.Y.) | 2024

von Montoya, S. | Bourcier, J. | Noviski, M. | +50

CommentIn: Nat Rev Drug Discov. 2024 Mar;23(3):173. - PMID 38336888

2

Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States : a real-world database study

enthalten in: Leukemia & lymphoma | 2023

von Eyre, T. | Hess, L. | Sugihara, T. | +8

3

Current Treatment of Chronic Lymphocytic Leukemia : The Diminishing Role of Chemoimmunotherapy

enthalten in: Drugs | 2022

von Roeker, L. | Thompson, M. | Mato, A.

4

All in the family : back-to-back kinase inhibitors for the treatment of chronic lymphocytic Leukemia

enthalten in: Haematologica | 2021

von Thompson, M. | Roeker, L. | Mato, A.

CommentOn: Haematologica. 2021 Sep 01;106(9):2364-2373. - PMID 33730844

5

Outcomes of COVID-19 in patients with CLL : a multicenter international experience

enthalten in: Blood | 2020

von Mato, A. | Roeker, L. | Lamanna, N. | +59

CommentIn: Blood. 2020 Sep 3;136(10):1115-1116. - PMID 32882019

6

BTK Inhibitors in Cancer Patients with COVID-19 : "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte)

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Chong, E. | Roeker, L. | Shadman, M. | +3

1
[1]